Clinical Trial Update: Safety Study of a Recombinant Protein Vaccine to Treat Esophageal Cancer [Phase 1]

View source ↗

Summary

A completed Phase 1 safety study evaluating a recombinant protein vaccine for esophageal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer

Drugs mentioned

• Recombinant protein vaccine

Snippet

Sponsor: ImmunoFrontier, Inc. | Conditions: Esophageal Cancer | Phase 1 | Status: COMPLETED